Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms ( LUTS ) .
This study indicated that Serenoa repens had the same effect in treating BPH compared with tamsulosin in terms of IPSS , QoL , and PVR after at least 6-month treatment cycle , however , the latter had a greater improvement in PV compared with the former .
And Serenoa repens did not increase the risk of adverse events especially with respect to ejaculation disorders and libido decrease
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
OBJECTIVE While the lipidosterolic extract ( LSESr ) of Serenoa repens -- Permixon -- has been shown to have an equivalent efficacy to finasteride in patients with benign prostatic hyperplasia ( BPH ) , to date , there has been no valid comparison of phytotherapy with alpha-blockers . The aim of this study was to assess the equivalent efficacy of Permixon and tamsulosin . METHODS Eight hundred and eleven men with symptomatic BPH ( international prost date symptom score , I-PSS > or = 10 ) were recruited in 11 European countries for a 12-month , double-blind r and omized trial . After a 4-week run-in period , 704 patients were r and omly assigned to either tamsulosin 0.4 mg per day ( N = 354 ) or Permixon 320 mg per day ( N = 350 ) . I-PSS , QoL and maximum urinary flow rate ( Qmax ) were evaluated at baseline and periodically for 1 year . Prostate volume and serum prostate-specific antigen ( PSA ) were measured at selection and at endpoint . The endpoint analysis was performed on the per- protocol ( PP ) population of 542 patients ( tamsulosin : N = 273 ; Permixon : N = 269 ) . RESULTS At 12 months , I-PSS decreased by 4.4 in each group and no differences were observed in either irritative or obstructive symptom improvements . The increase in Qmax was similar in both treatment groups ( 1.8 ml/s Permixon , 1.9 ml/s tamsulosin ) . PSA remained stable while prostate volume decreased slightly in the Permixon-treated patients . The two compounds were well tolerated , however , ejaculation disorders occurred more frequently in the tamsulosin group . CONCLUSION This study demonstrated that Permiwon and tamsulosin are equivalent in the medical treatment of lower urinary tract symptoms in men with BPH , during and up to 12 months of therapy
Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms ( LUTS ) .
This study indicated that Serenoa repens had the same effect in treating BPH compared with tamsulosin in terms of IPSS , QoL , and PVR after at least 6-month treatment cycle , however , the latter had a greater improvement in PV compared with the former .
And Serenoa repens did not increase the risk of adverse events especially with respect to ejaculation disorders and libido decrease